Diamyd Medical Toekomstige groei

Future criteriumcontroles 2/6

De winst van Diamyd Medical zal naar verwachting dalen met 10.3% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 103% per jaar. De winst per aandeel zal naar verwachting afnemen met 5.7% per jaar.

Belangrijke informatie

-10.3%

Groei van de winst

-5.7%

Groei van de winst per aandeel

Biotechs winstgroei	45.7%
Inkomstengroei	103.0%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	22 Nov 2024

Recente toekomstige groei-updates

Recent updates

We're Keeping An Eye On Diamyd Medical's (STO:DMYD B) Cash Burn Rate

Feb 02

We Think Diamyd Medical (STO:DMYD B) Needs To Drive Business Growth Carefully

Sep 22

What You Need To Know About Diamyd Medical AB (publ)'s (STO:DMYD B) Investor Composition

Jan 22

Here's Why Diamyd Medical's (STO:DMYD B) Statutory Earnings Are Arguably Too Conservative

Nov 30

Winst- en omzetgroeiprognoses

OM:DMYD B - Toekomstschattingen van analisten en financiële gegevens uit het verleden (SEK Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
8/31/2027	38	N/A	N/A	N/A	1
8/31/2026	3	-186	-181	-181	1
8/31/2025	3	-159	-139	-155	1
8/31/2024	0	-152	-137	-129	N/A
5/31/2024	0	-140	-144	-135	N/A
2/29/2024	0	-120	-134	-122	N/A
11/30/2023	0	-116	-124	-112	N/A
8/31/2023	1	-116	-122	-111	N/A
5/31/2023	1	-119	-116	-119	N/A
2/28/2023	0	-115	-122	-127	N/A
11/30/2022	1	-99	-114	-120	N/A
8/31/2022	0	-104	-128	-93	N/A
5/31/2022	0	-91	-153	-110	N/A
2/28/2022	1	-106	-147	-99	N/A
11/30/2021	0	-83	-140	-95	N/A
8/31/2021	0	60	-114	-109	N/A
5/31/2021	0	74	-67	-58	N/A
2/28/2021	0	99	-47	-43	N/A
11/30/2020	0	121	5	9	N/A
8/31/2020	0	10	15	17	N/A
5/31/2020	1	13	13	13	N/A
2/29/2020	1	13	11	11	N/A
11/30/2019	1	-35	-35	-35	N/A
8/31/2019	2	-37	-39	-39	N/A
5/31/2019	1	-38	-38	-38	N/A
2/28/2019	0	-43	-38	-38	N/A
11/30/2018	0	-42	-41	-40	N/A
8/31/2018	1	-44	-42	-42	N/A
5/31/2018	1	-39	N/A	-42	N/A
2/28/2018	1	-35	N/A	-38	N/A
11/30/2017	1	-32	N/A	-33	N/A
8/31/2017	1	-26	N/A	-26	N/A
5/31/2017	1	-24	N/A	-20	N/A
2/28/2017	1	-34	N/A	-19	N/A
11/30/2016	1	-32	N/A	-18	N/A
8/31/2016	1	-32	N/A	-18	N/A
5/31/2016	1	-31	N/A	-17	N/A
2/29/2016	1	-20	N/A	-18	N/A
11/30/2015	1	-20	N/A	-17	N/A
8/31/2015	1	-21	N/A	-18	N/A
5/31/2015	1	-20	N/A	-18	N/A
2/28/2015	0	-17	N/A	-17	N/A
11/30/2014	0	-17	N/A	-18	N/A
8/31/2014	0	-16	N/A	-17	N/A
5/31/2014	0	-17	N/A	-17	N/A
2/28/2014	0	-17	N/A	-16	N/A
11/30/2013	0	-18	N/A	-15	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat DMYD B de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat DMYD B de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat DMYD B de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van DMYD B ( 103% per jaar) zal naar verwachting sneller groeien dan de markt Swedish ( -0% per jaar).

Hoge groei-inkomsten: De omzet van DMYD B ( 103% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van DMYD B naar verwachting over 3 jaar hoog zal zijn

Diamyd Medical Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 27% to kr19.00

Price target increased to kr19.50

Price target increased to kr19.50

Recent updates

Diamyd Medical AB (publ) Hits a Recruitment Milestone in DIAGNODE-3 Phase 3 Trial

Diamyd Medical AB (publ), Annual General Meeting, Dec 05, 2024

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Diamyd Medical AB (publ) to Report Q1, 2025 Results on Jan 29, 2025

CEO & President exercised options to buy kr660k worth of stock.

Diamyd Medical to Pursue Accelerated Approval Pathway for Type 1 Diabetes Precision Medicine

Diamyd Medical Announces Positive Interim Analysis Results for Phase 3 Trial in Type 1 Diabetes

New major risk - Share price stability

Third quarter 2024 earnings released

Diamyd Medical AB (publ) to Report Q4, 2024 Results on Nov 14, 2024

Diamyd Medical AB (publ) Updates on the Registrational Phase 3 Trial

Independent Chairman recently sold kr651k worth of stock

Recruitment Milestone Reaches in Diamyd® Phase 3 Trial

Second quarter 2024 earnings released

New minor risk - Share price stability

We're Keeping An Eye On Diamyd Medical's (STO:DMYD B) Cash Burn Rate

First quarter 2024 earnings released

In-Depth Analysis of Diamyd Medical AB (publ)'s Phase II Trial Further Supports Value of Presented Insulin Production

Diamyd Medical's Precision Medicine Patent for the Prevention and Treatment of Autoimmune Diabetes Granted in South Korea

Diamyd Medical AB (Publ) Elects Karin Rosén as A New Member of the Board

Diamyd Medical AB (publ) to Report Fiscal Year 2023 Results on Nov 30, 2023

Chairman recently bought kr72k worth of stock

Diamyd Medical AB (publ) has completed a Composite Units Offering in the amount of SEK 69.834709 million.

Diamyd Medical AB (Publ) Announces Follow-Up Study Recommends Diamyd to Offer Advantages in Delivering Type 1 Diabetes Onset

Diamyd Medical AB (publ) Announces Preliminary Results from Booster Trial with Diamyd Provide Additional Support for Intralymphatic Injection

Diamyd Medical AB (publ) to Report Q2, 2024 Results on Mar 27, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Diamyd Medical AB (Publ) Announces Changes of the Board

We Think Diamyd Medical (STO:DMYD B) Needs To Drive Business Growth Carefully

Diamyd Medical AB (Publ) Announces Registrational Phase III Trial in Type 1 Diabetes with Diamyd Expands to the US

New minor risk - Shareholder dilution

Price target decreased by 27% to kr19.00

Diamyd Medical AB (publ), Annual General Meeting, Nov 30, 2023

Third quarter 2023 earnings released

CEO & President recently bought kr88k worth of stock

Second quarter 2023 earnings released

Diamyd Medical Receives Patent Protection in the US and Japan for Gaba Formulation Remygen

First quarter 2023 earnings released: kr0.43 loss per share (vs kr0.52 loss in 1Q 2022)

Diamyd Medical Precision Medicine Patent for Prevention and Treatment of Autoimmune Diabetes to Be Granted in Eurasia

Diamyd Medical AB (Publ) Announces US Partial Clinical Hold on Diamyd® Phase III Trial Lifted by the FDA

Price target increased to kr19.50

Full year 2022 earnings released: kr1.35 loss per share (vs kr0.86 profit in FY 2021)

All Patients in DIAGNODE-B Have Received an Additional (Booster) Injection of Diamyd

Diamyd Medical AB (publ) to Report Q3, 2023 Results on Jun 28, 2023

Third quarter 2022 earnings released

Diamyd Medical AB (publ), Annual General Meeting, Dec 01, 2022

Diamyd Medical AB (publ) Announces First Patient Enrolled in its Phase III Trial DIAGNODE-3

Price target increased to kr19.50

Director recently sold kr1.0m worth of stock

Diamyd Medical AB Announces New Clinical Trial Will Evaluate an Additional Injection (Booster) with Diamyd

Second quarter 2022 earnings: Revenues miss analyst expectations

Clinical Trial in Type 1 Diabetes with Diamyd Medical's Remygen Is Fully Recruited

Diamyd Medical Proceeds with Initiation of Type 1 Diabetes Phase III Trial in Europe

First quarter 2022 earnings: Revenues miss analyst expectations

Diamyd Medical AB Patent for Intralymphatic Injection of GAD in Autoimmune Diabetes to Be Granted in China

Diamyd Medical Announces Australia Grants as the First Region Diamyd Medical A Broadening of A Patent for Intralymphatic Injection of Antigens in Autoimmune Diabetes

Director recently sold kr3.7m worth of stock

Diamyd Medical Pauses Start of Phase III Trial

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS kr0.86 (vs kr0.14 in FY 2020)

CEO & President recently bought kr112k worth of stock

CEO & President recently bought kr112k worth of stock

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS kr0.84 (vs kr0.14 in FY 2020)

Diamyd Medical AB Receives First Regulatory Approval to Start the Phase III Trial DIAGNODE-3 with the Diabetes Vaccine Diamyd®

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released

Diamyd Medical AB (Publ) Announces 24-Month Follow-Up of Phase IIb Diamyd® Clinical Trial Indicates Continued Similar Progression After 15 Months

Investor sentiment improved over the past week

the 24-Month Follow-Up of DIAGNODE-2 with the Diabetes Vaccine Diamyd® Will Be Presented in Early July

Director recently sold kr267k worth of stock